Therma Bright Launches Benepod.com eCommerce Website

The Innovative Hot & Cold Contrast Therapy Device for Relief of Chronic Pain

Toronto, Ontario–(Newsfile Corp. – November 24, 2021) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the launch of its eCommerce site – https://www.benepod.com just in time for the 2021 Holiday Season.

Benepod for chronic pain

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/3127/104946_benepod.jpg

The Benepod is a small hand-held, hot/cold contrast therapy device for relief of chronic pain and muscle soreness. The device was specifically designed for people seeking relief from chronic pain, including Osteoarthritis of the hands, lower back pain, chronic tendonitis conditions, chronic musculoskeletal pain, neuropathic pain, planter fasciitis, migraines and headaches, sciatica, carpal tunnel and fibromyalgia.

“We’re excited to launch the first of three (3) new eCommerce websites for the 2021 Holiday Season,” expressed Rob Fia, CEO of Therma Bright. “The Benepod is a great holiday gift for yourself, a family member or friend. If you seek relief from chronic pain, Benepod delivers.”

In the coming weeks, the Company plans to launch two (2) more eCommerce sites, – one featuring the Venowave – a Deep Vein Thrombosis medical device that utilizes wave motion massage to prevent blood clots and the other featuring InterceptCS – a device that prevents cold sores before they appear.

About Therma Bright Inc.

Therma Bright, developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today’s most important medical and healthcare challenges. The Company’s initial breakthrough proprietary technology delivers effective, non-invasive, and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). For more information visit: www.thermabright.com.

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us on Twitter

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute “forward-looking” statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation. as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104946